Análise molecular de polimorfismos e expressão gênica do fator β1 de transformação do crescimento (TGF-β1) no câncer de próstata

• Ano de defesa: 2005
• Autor(a) principal: Faria, Paula Cristina Batista de
• Tipo de documento: Dissertação
• Tipo de acesso: Acesso aberto
• Idioma: por
• Instituição de defesa: Universidade Federal de Uberlândia; Brasil; Programa de Pós-graduação em Genética e Bioquímica
• Palavras-chave em Português: Câncer de próstata; Câncer de pele não melanoma; CNPQ::CIENCIAS BIOLOGICAS::GENETICA
• Link de acesso: https://repositorio.ufu.br/handle/123456789/27031; http://dx.doi.org/10.14393/ufu.di.2005.9

In recent decades, prostate cancer has emerged as one of the most common diseases among older men. In Brazil and the United States is the second most commonly diagnosed after non-melanoma skin cancer. Also, it is the second cause of death in men after lung cancer. Among the cytokines that make up the family of Transforming Growth Factors p (TGF-ps), TGF-pi is most often overexpressed in tumor cells and plays a central role in tumor transformation and progression as well as tumor repression; being the main focus of most studies on the role of growth factors in tumorigenesis. Several studies have shown that somatic mutations in TGF-β1 and other components of its signaling pathway are also associated with tumor development. In the present study, TGF-β1 gene expression in peripheral blood samples from patients with prostate adenocarcinoma (CaP) and benign prostatic hyperplasia (BPH) was evaluated by semi-quantitative RT-PCR. clinical presentation of patients, disease staging, and also the presence of the LeulOPro (T and C alleles) and Arg25Pro (alleles G and C) polymorphisms, present in exon 1 of the TGFB1 gene. The technique used for patient genotyping was PCR-ARMS, which proved to be very efficient for this. No statistically significant differences were observed between the genotypes and the patient groups analyzed. However, the presence of the C allele in Codon 10 may be involved in the progression of cancer once installed, since a trend was observed between patients with CaP and patients with this disease. allele in presenting a higher Gleason score. We also found a higher level of TGFB1 gene transcripts in patients with CaP, suggesting that this may be a potential serum biomarker for prostate cancer. However, subsequent studies are needed to better understand the role of this cytokine in the development and progression of this disease.